Abstract | RATIONALE: OBJECTIVE: To determine if PLV would have an impact on outcome in patients with ARDS. METHODS: RESULTS: The 28-d mortality in the CMV group was 15%, versus 26.3% in the low-dose (p=0.06) and 19.1% in the high-dose (p=0.39) PLV groups. There were more ventilator-free days in the CMV group (13.0+/-9.3) compared with both the low-dose (7.4+/-8.5; p<0.001) and high-dose (9.9+/-9.1; p=0.043) groups. There were more pneumothoraces, hypoxic episodes, and hypotensive episodes in the PLV patients. CONCLUSIONS: PLV at both high and low doses did not improve outcome in ARDS compared with CMV and cannot be recommended for patients with ARDS.
|
Authors | Robert M Kacmarek, Herbert P Wiedemann, Philip T Lavin, Mark K Wedel, Ahmet S Tütüncü, Arthur S Slutsky |
Journal | American journal of respiratory and critical care medicine
(Am J Respir Crit Care Med)
Vol. 173
Issue 8
Pg. 882-9
(Apr 15 2006)
ISSN: 1073-449X [Print] United States |
PMID | 16254269
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Dose-Response Relationship, Drug
- Female
- Fluorocarbons
(administration & dosage, therapeutic use)
- Follow-Up Studies
- Humans
- Instillation, Drug
- Liquid Ventilation
(methods)
- Male
- Middle Aged
- Respiratory Distress Syndrome
(mortality, therapy)
- Retrospective Studies
- Survival Rate
- Treatment Outcome
|